342 related articles for article (PubMed ID: 11590213)
1. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice.
Jong MC; Rensen PC; Dahlmans VE; van der Boom H; van Berkel TJ; Havekes LM
J Lipid Res; 2001 Oct; 42(10):1578-85. PubMed ID: 11590213
[TBL] [Abstract][Full Text] [Related]
2. ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression.
Gerritsen G; Rensen PC; Kypreos KE; Zannis VI; Havekes LM; Willems van Dijk K
J Lipid Res; 2005 Jul; 46(7):1466-73. PubMed ID: 15863838
[TBL] [Abstract][Full Text] [Related]
3. Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL.
Westerterp M; de Haan W; Berbée JF; Havekes LM; Rensen PC
J Lipid Res; 2006 Jun; 47(6):1203-11. PubMed ID: 16537968
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV.
Goldberg IJ; Scheraldi CA; Yacoub LK; Saxena U; Bisgaier CL
J Biol Chem; 1990 Mar; 265(8):4266-72. PubMed ID: 2307668
[TBL] [Abstract][Full Text] [Related]
5. Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.
Berbée JF; van der Hoogt CC; Sundararaman D; Havekes LM; Rensen PC
J Lipid Res; 2005 Feb; 46(2):297-306. PubMed ID: 15576844
[TBL] [Abstract][Full Text] [Related]
6. Resistance of chylomicron and VLDL remnants to post-heparin lipolysis in ApoE-deficient mice: the role of apoE in lipoprotein lipase-mediated lipolysis in vivo and in vitro.
Zsigmond E; Fuke Y; Li L; Kobayashi K; Chan L
J Lipid Res; 1998 Sep; 39(9):1852-61. PubMed ID: 9741698
[TBL] [Abstract][Full Text] [Related]
7. Evidence that cholesteryl ester and triglyceride accumulation in J774 macrophages induced by very low density lipoprotein subfractions occurs by different mechanisms.
Evans AJ; Sawyez CG; Wolfe BM; Connelly PW; Maguire GF; Huff MW
J Lipid Res; 1993 May; 34(5):703-17. PubMed ID: 8509711
[TBL] [Abstract][Full Text] [Related]
8. A decreased expression of angiopoietin-like 3 is protective against atherosclerosis in apoE-deficient mice.
Ando Y; Shimizugawa T; Takeshita S; Ono M; Shimamura M; Koishi R; Furukawa H
J Lipid Res; 2003 Jun; 44(6):1216-23. PubMed ID: 12671033
[TBL] [Abstract][Full Text] [Related]
9. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
10. [THE LIPOLYSIS IN PHYLOGENETICALLY EARLY LIPOPROTEINS OF LOW DENSITY AND MORE LATER LIPOPROTEINS OF VERY LOW DENSITY: FUNCTION AND DIAGNOSTIC VALUE OF APOE AND APOC-III].
Rozhkova TA; Titov VN; Amelyushkina VA; Kaba SI; Kukhartchuk VV
Klin Lab Diagn; 2015 Dec; 60(12):4-14. PubMed ID: 27032246
[TBL] [Abstract][Full Text] [Related]
11. Influence of lipoprotein lipase and hepatic lipase on the transformation of VLDL and HDL during lipolysis of VLDL.
Murdoch SJ; Breckenridge WC
Atherosclerosis; 1995 Dec; 118(2):193-212. PubMed ID: 8770314
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the lipid-binding properties and lipoprotein lipase inhibition of a novel apolipoprotein C-III variant Ala23Thr.
Liu H; Labeur C; Xu CF; Ferrell R; Lins L; Brasseur R; Rosseneu M; Weiss KM; Humphries SE; Talmud PJ
J Lipid Res; 2000 Nov; 41(11):1760-71. PubMed ID: 11060345
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein lipase- and hepatic triglyceride lipase- promoted very low density lipoprotein degradation proceeds via an apolipoprotein E-dependent mechanism.
Medh JD; Fry GL; Bowen SL; Ruben S; Wong H; Chappell DA
J Lipid Res; 2000 Nov; 41(11):1858-71. PubMed ID: 11060356
[TBL] [Abstract][Full Text] [Related]
14. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
Aalto-Setälä K; Weinstock PH; Bisgaier CL; Wu L; Smith JD; Breslow JL
J Lipid Res; 1996 Aug; 37(8):1802-11. PubMed ID: 8864964
[TBL] [Abstract][Full Text] [Related]
15. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size.
Breyer ED; Le NA; Li X; Martinson D; Brown WV
J Lipid Res; 1999 Oct; 40(10):1875-82. PubMed ID: 10508207
[TBL] [Abstract][Full Text] [Related]
17. Effects of apoA-V on HDL and VLDL metabolism in APOC3 transgenic mice.
Qu S; Perdomo G; Su D; D'Souza FM; Shachter NS; Dong HH
J Lipid Res; 2007 Jul; 48(7):1476-87. PubMed ID: 17438339
[TBL] [Abstract][Full Text] [Related]
18. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.
Schaap FG; Rensen PC; Voshol PJ; Vrins C; van der Vliet HN; Chamuleau RA; Havekes LM; Groen AK; van Dijk KW
J Biol Chem; 2004 Jul; 279(27):27941-7. PubMed ID: 15090553
[TBL] [Abstract][Full Text] [Related]
19. Effect of the APOC3 Sst I SNP on fasting triglyceride levels in men heterozygous for the LPL P207L deficiency.
Garenc C; Couillard C; Laflamme N; Cadelis F; Gagné C; Couture P; Julien P; Bergeron J
Eur J Hum Genet; 2005 Oct; 13(10):1159-65. PubMed ID: 16015281
[TBL] [Abstract][Full Text] [Related]
20. Characterization of very low density lipoproteins and intermediate density lipoproteins of normo- and hyperlipidemic apolipoprotein E-2 homozygotes.
Schmitz G; Assmann G; Augustin J; Dirkes-Kersting A; Brennhaüsen B; Karoff C
J Lipid Res; 1985 Mar; 26(3):316-26. PubMed ID: 3989390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
